Literature DB >> 18650391

A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys.

Sampa Santra1, Bette T Korber, Mark Muldoon, Dan H Barouch, Gary J Nabel, Feng Gao, Beatrice H Hahn, Barton F Haynes, Norman L Letvin.   

Abstract

One of the major challenges that must be met in developing an HIV-1 vaccine is devising a strategy to generate cellular immunity with sufficient breadth to deal with the extraordinary genetic diversity of the virus. Amino acids in the envelopes of viruses from the same clade can differ by >15%, and those from different clades can differ by >30%. It has been proposed that creating immunogens using centralized HIV-1 gene sequences might provide a practical solution to this problem. Such centralized genes can be generated by employing a number of different strategies: consensus, ancestral, or center of tree sequences. These computer-generated sequences are a shorter genetic distance from any two contemporary virus sequences than those contemporary sequences are from each other. The present study was initiated to evaluate the breadth of cellular immunity generated through immunization of rhesus monkeys with vaccine constructs expressing either an HIV-1 global consensus envelope sequence (CON-S) or a single patient isolate clade B envelope sequence (clade B). We show that vaccine immunogens expressing the single centralized gene CON-S generated cellular immune responses with significantly increased breadth compared with immunogens expressing a wild-type virus gene. In fact, CON-S immunogens elicited cellular immune responses to 3- to 4-fold more discrete epitopes of the envelope proteins from clades A, C, and G than did clade B immunogens. These findings suggest that immunization with centralized genes is a promising vaccine strategy for developing a global vaccine for HIV-1 as well as vaccines for other genetically diverse viruses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18650391      PMCID: PMC2483234          DOI: 10.1073/pnas.0803352105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.

Authors:  Bimal K Chakrabarti; Wing-pui Kong; Bei-yue Wu; Zhi-Yong Yang; Jacques Friborg; Xu Ling; Steven R King; David C Montefiori; Gary J Nabel
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Authors:  Ronald Vogels; David Zuijdgeest; Richard van Rijnsoever; Eric Hartkoorn; Irma Damen; Marie-Pierre de Béthune; Stefan Kostense; Germaine Penders; Niels Helmus; Wouter Koudstaal; Marco Cecchini; Antoinette Wetterwald; Mieke Sprangers; Angelique Lemckert; Olga Ophorst; Björn Koel; Michelle van Meerendonk; Paul Quax; Laura Panitti; Jos Grimbergen; Abraham Bout; Jaap Goudsmit; Menzo Havenga
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

3.  Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV.

Authors:  Xiaoyan Zhan; Louis N Martin; Karen S Slobod; Chris Coleclough; Timothy D Lockey; Scott A Brown; John Stambas; Mattia Bonsignori; Robert E Sealy; James L Blanchard; Julia L Hurwitz
Journal:  Vaccine       Date:  2005-07-20       Impact factor: 3.641

4.  Genetic characterization of diverse HIV-1 strains in an immigrant population living in New York City.

Authors:  Hsi-Hsun Lin; Brian K Gaschen; Mary Collie; Mona El-Fishaway; Zhiwei Chen; Bette T Korber; Sally T Beatrice; Linqi Zhang
Journal:  J Acquir Immune Defic Syndr       Date:  2006-04-01       Impact factor: 3.731

5.  A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses.

Authors:  Hua-Xin Liao; Laura L Sutherland; Shi-Mao Xia; Mary E Brock; Richard M Scearce; Stacie Vanleeuwen; S Munir Alam; Mildred McAdams; Eric A Weaver; Zenaido Camacho; Ben-Jiang Ma; Yingying Li; Julie M Decker; Gary J Nabel; David C Montefiori; Beatrice H Hahn; Bette T Korber; Feng Gao; Barton F Haynes
Journal:  Virology       Date:  2006-09-30       Impact factor: 3.616

6.  Ancestral and consensus envelope immunogens for HIV-1 subtype C.

Authors:  Denise L Kothe; Yingying Li; Julie M Decker; Frederic Bibollet-Ruche; Kenneth P Zammit; Maria G Salazar; Yalu Chen; Zhiping Weng; Eric A Weaver; Feng Gao; Barton F Haynes; George M Shaw; Bette T M Korber; Beatrice H Hahn
Journal:  Virology       Date:  2006-06-14       Impact factor: 3.616

7.  Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.

Authors:  Shixia Wang; Ranajit Pal; John R Mascola; Te-Hui W Chou; Innocent Mboudjeka; Siyuan Shen; Qin Liu; Stephen Whitney; Timothy Keen; B C Nair; V S Kalyanaraman; Philip Markham; Shan Lu
Journal:  Virology       Date:  2006-04-17       Impact factor: 3.616

8.  Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope.

Authors:  N A Doria-Rose; G H Learn; A G Rodrigo; D C Nickle; F Li; M Mahalanabis; M T Hensel; S McLaughlin; P F Edmonson; D Montefiori; S W Barnett; N L Haigwood; J I Mullins
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.

Authors:  Norman L Letvin; Yue Huang; Bimal K Chakrabarti; Ling Xu; Michael S Seaman; Kristin Beaudry; Birgit Korioth-Schmitz; Faye Yu; Daniela Rohne; Kristi L Martin; Ayako Miura; Wing-Pui Kong; Zhi-Yong Yang; Rebecca S Gelman; Olga G Golubeva; David C Montefiori; John R Mascola; Gary J Nabel
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

Review 10.  GP120: target for neutralizing HIV-1 antibodies.

Authors:  Ralph Pantophlet; Dennis R Burton
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

View more
  40 in total

Review 1.  T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces.

Authors:  Bette T Korber; Norman L Letvin; Barton F Haynes
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

2.  Minor viral and host genetic polymorphisms can dramatically impact the biologic outcome of an epitope-specific CD8 T-cell response.

Authors:  Christof Geldmacher; Ian S Metzler; Sodsai Tovanabutra; Tedi E Asher; Emma Gostick; David R Ambrozak; Constantinos Petrovas; Alexandra Schuetz; Njabulo Ngwenyama; Gustavo Kijak; Leonard Maboko; Michael Hoelscher; Francine McCutchan; David A Price; Daniel C Douek; Richard A Koup
Journal:  Blood       Date:  2009-06-19       Impact factor: 22.113

3.  High-throughput quantitative real-time polymerase chain reaction array for absolute and relative quantification of rhesus macaque types I, II, and III interferon and their subtypes.

Authors:  Lynnsie M Schramm; Kevin D Kirschman; Melissa Heuer; Aaron A Chen; Daniela Verthelyi; Montserrat Puig; Ronald L Rabin
Journal:  J Interferon Cytokine Res       Date:  2012-07-20       Impact factor: 2.607

4.  Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions.

Authors:  E A Weaver; Z T Camacho; F Gao
Journal:  AIDS Res Hum Retroviruses       Date:  2010-05       Impact factor: 2.205

5.  Hepatitis C genotype 1 mosaic vaccines are immunogenic in mice and induce stronger T-cell responses than natural strains.

Authors:  Karina Yusim; Rebecca Dilan; Erica Borducchi; Kelly Stanley; Elena Giorgi; William Fischer; James Theiler; Joseph Marcotrigiano; Bette Korber; Dan H Barouch
Journal:  Clin Vaccine Immunol       Date:  2012-12-05

Review 6.  HIV-1 vaccine development after STEP.

Authors:  Dan H Barouch; Bette Korber
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

7.  Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys.

Authors:  Dan H Barouch; Kara L O'Brien; Nathaniel L Simmons; Sharon L King; Peter Abbink; Lori F Maxfield; Ying-Hua Sun; Annalena La Porte; Ambryice M Riggs; Diana M Lynch; Sarah L Clark; Katherine Backus; James R Perry; Michael S Seaman; Angela Carville; Keith G Mansfield; James J Szinger; Will Fischer; Mark Muldoon; Bette Korber
Journal:  Nat Med       Date:  2010-02-21       Impact factor: 53.440

8.  Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys.

Authors:  Sampa Santra; Hua-Xin Liao; Ruijin Zhang; Mark Muldoon; Sydeaka Watson; Will Fischer; James Theiler; James Szinger; Harikrishnan Balachandran; Adam Buzby; David Quinn; Robert J Parks; Chun-Yen Tsao; Angela Carville; Keith G Mansfield; George N Pavlakis; Barbara K Felber; Barton F Haynes; Bette T Korber; Norman L Letvin
Journal:  Nat Med       Date:  2010-02-21       Impact factor: 53.440

9.  Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species.

Authors:  Lisa E Hensley; Sabue Mulangu; Clement Asiedu; Joshua Johnson; Anna N Honko; Daphne Stanley; Giulia Fabozzi; Stuart T Nichol; Thomas G Ksiazek; Pierre E Rollin; Victoria Wahl-Jensen; Michael Bailey; Peter B Jahrling; Mario Roederer; Richard A Koup; Nancy J Sullivan
Journal:  PLoS Pathog       Date:  2010-05-20       Impact factor: 6.823

10.  Sang Froid in a time of trouble: is a vaccine against HIV possible?

Authors:  Stanley A Plotkin
Journal:  J Int AIDS Soc       Date:  2009-02-02       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.